Clinical Trials

Other hematologic neoplasm

1,186 enrolled

Leukemia, Myeloid, Acute

NCT06956001 2026-02-12

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

380 enrolled

Thoracic

NSCLC Patients With Brain Metastasis

NCT06752811 2026-02-10

pompom

416 enrolled

Pancreatic Cancer Metastatic

NCT05020236 2026-02-02

MAGNETISMM-5

944 enrolled

Plasma cell

Multiple Myeloma

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

400 enrolled

Triple Negative Breast Neoplasms

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

280 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07043725 2025-09-23

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

544 enrolled

HER2-positive Breast Cancer

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

390 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

246 enrolled

Breast Neoplasms

NCT07003074 2025-06-25

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

642 enrolled

Breast Neoplasms

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

480 enrolled

Cholangiocarcinoma

NCT03903835 2025-04-09

ProBio

750 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04996017 2025-03-13

AtezoMeso

Other solid neoplasmThoracic

162 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT06612151 2025-02-11

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

438 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

416 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06754085 2024-12-31

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

131 enrolled

Genitourinary

Prostatic Neoplasms

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT06296706 2024-11-14

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

630 enrolled

Stomach Neoplasms

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

460 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

376 enrolled

Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

NCT05754853 2023-04-13

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer